Andrea Nozza

Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

Influence of Pre- and Post-Transplantation Responses on Outcome of Patients With Multiple Myeloma: Sequential Improvement of Response and Achievement of Complete Response Are Associated With Longer Survival

Treatment of Vascular Rejection With Rituximab in Cardiac Transplantation

Monoclonal Gammopathy–Associated Peripheral Neuropathy: Diagnosis and Management

Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose

Clinical, hematological and cytogenetic characteristics of atypical chronic myeloid leukemia

Perspectives on cancer therapy-induced mucosal injury

Paraneoplastic Syndromes Involving the Nervous System

Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience

Amifostine

Tumour immunity: effector response to tumour and role of the microenvironment

The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence

MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy

Diagnosis and treatment of chronic acquired demyelinating polyneuropathies

Retrospective Analysis of the Safety of Herceptin^® Immunotherapy in Metastatic Breast Cancer

Dose intensity of chemotherapy for osteosarcoma and outcome in the Cooperative Osteosarcoma Study Group (COSS) trials

Osteosarcoma treatment – Where do we stand? A state of the art review

Human FoxP3+ regulatory T cells in systemic autoimmune diseases

Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE

2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours

Iron oxide MR contrast agents for molecular and cellular imaging

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010

New treatments for SLE: cell-depleting and anti-cytokine therapies

Anti-CD20 (rituximab) treatment improves atopic eczema

MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy

Neuropathy and paraproteins: review of a complex association

Plasma exchanges for severe acute neurological deterioration in patients with IgM anti-myelin-associated glycoprotein (anti-MAG) neuropathy

Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue

Recipient CD4+ T cells that survive irradiation regulate chronic graft-versus-host disease

Cost Effectiveness of Positron Emission Tomography in Patients With Hodgkin's Lymphoma in Unconfirmed Complete Remission or Partial Remission After First-Line Therapy

ICRP PUBLICATION 118: ICRP Statement on Tissue Reactions and Early and Late Effects of Radiation in Normal Tissues and Organs — Threshold Doses for Tissue Reactions in a Radiation Protection Context

Immunologic and Clinical Responses to Rituximab in a Child With Opsoclonus-Myoclonus Syndrome

Conversion of Alloantigen-Specific CD8+ T Cell Anergy to CD8+ T Cell Priming through In Vivo Ligation of Glucocorticoid-Induced TNF Receptor

Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification

Multiple Myeloma

The World Health Organization (WHO) classification of the myeloid neoplasms

Photopharmacology: Beyond Proof of Principle

Predictive value of early 18F‐fluorodeoxyglucose positron emission tomography (FDG‐PET) during salvage chemotherapy in relapsing/refractory Hodgkin lymphoma (HL) treated with high‐dose chemotherapy

Reduced intensity conditioning regimen followed by glycosylated G-CSF mobilized PBSCT in patients with solid tumors and malignant lymphomas

Advances in the Treatment of Paraproteinemic Neuropathy

Intensified CHOP regimen in aggressive lymphomas:maximal dose intensity and dose density of doxorubicin and cyclophosphamide

Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma

Ex vivo manipulation of hematopoietic stem cells for transplantation: the potential role of amifostine.

SERUM VEGF LEVELS IN POEMS SYNDROME AND IN IMMUNE-MEDIATED NEUROPATHIES

New reciprocal translocation t(5;10)(q33;q22) associated with atypical chronic myeloid leukemia.

Plateau phase in multiple myeloma: an end-point of conventional-dose chemotherapy.